Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Gulati

Showing results (101-110 of 154) with videos related to

Pageof 16
Sort By:
Plos One|June 2, 2018
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
The Prostate|October 30, 2009
The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cellsColm Morrissey, Janice S Lai, Lisha G Brown, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2024
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Ridvan Arda Demirci, Roman Gulati, Jessica E Hawley, et al.
Plos One|August 16, 2018
Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
Pharmacoeconomics|October 6, 2022
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP TrialEdna Keeney, Sabina Sanghera, Richard M Martin, et al.
Nature Communications|March 4, 2021
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profilingLauren Brady, Michelle Kriner, Ilsa Coleman, et al.
Cancer|February 14, 2024
The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillanceJonathan L Wright, Jeannette M Schenk, Roman Gulati, et al.
JAMA Network Open|February 14, 2025
Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen ScreeningDana H Chung, Tanner J Caverly, Matthew J Schipper, et al.
NEJM Evidence|June 20, 2022
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black MenSpyridon P Basourakos, Roman Gulati, Randy A Vince, et al.
The Journal of Urology|January 9, 2023
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical TrialMichael T Schweizer, Lawrence True, Roman Gulati, et al.
Pageof 16

Showing results (101-110 of 154) with videos related to

Sort By:
Pageof 16
Plos One|June 2, 2018
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
The Prostate|October 30, 2009
The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cellsColm Morrissey, Janice S Lai, Lisha G Brown, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2024
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Ridvan Arda Demirci, Roman Gulati, Jessica E Hawley, et al.
Plos One|August 16, 2018
Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
Pharmacoeconomics|October 6, 2022
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP TrialEdna Keeney, Sabina Sanghera, Richard M Martin, et al.
Nature Communications|March 4, 2021
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profilingLauren Brady, Michelle Kriner, Ilsa Coleman, et al.
Cancer|February 14, 2024
The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillanceJonathan L Wright, Jeannette M Schenk, Roman Gulati, et al.
JAMA Network Open|February 14, 2025
Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen ScreeningDana H Chung, Tanner J Caverly, Matthew J Schipper, et al.
NEJM Evidence|June 20, 2022
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black MenSpyridon P Basourakos, Roman Gulati, Randy A Vince, et al.
The Journal of Urology|January 9, 2023
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical TrialMichael T Schweizer, Lawrence True, Roman Gulati, et al.
Pageof 16